Search
EHA 2026: Legend Biotech CEO Ying Huang discusses the company's late-breaking in vivo CAR-T presentation showing a 6/6 overall response and 5/6 complete response at the highest dose level in NHL
LB2501 is a CD19/CD20 dual targeting CAR-T. He discusses the EHA data, and next steps for the program. Plus, a review of last week's DLL3 data from ASCO and how he thinks about partnering and the competitive landscape.
Jun 14
ASH 2025: Legend Biotech CEO Ying Huang discusses new long-term Carvykti data, looming competition, a CD19+CD20 γδ program, and in vivo CAR-T
He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs. Coverage brought to you by
Dec 6, 2025
Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia
He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.
Nov 13, 2025
ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors
He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2...
Jun 1, 2025
ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more
He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future...
Dec 9, 2024
Legend Biotech's CEO Ying Huang on moving CARVYKTI into earlier lines of treatment in the E.U. and U.S.
Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting, and highlight's Legend's pipeline.
Feb 26, 2024
.png){kind=logo}